Denali Therapeutics Inc. Profile Avatar - Palmy Investing

Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…

Biotechnology
US, South San Francisco [HQ]
End of DNLI's Analysis
CIK: 1714899 CUSIP: 24823R105 ISIN: US24823R1059 LEI: - UEI: -
Secondary Listings
DNLI has no secondary listings inside our databases.